Abstract
Guillain-Barré syndrome (GBS) is an immune-mediated demyelinating disorder which attacks the peripheral nervous system. Antecedent infection or vaccine administration are known to precipitate the onset of this disorder. Its typical presentation leads to a symmetric, rapidly progressive, ascending paresis with associated sensory deficits and impaired reflexes. We present a rare case of a bi-facial diplegia variant of GBS, within four weeks of the COVID-19 vaccination. Due to its chronology, clinical manifestations, and cerebrospinal fluid (CSF) findings, we propose this case to be a rare complication of the COVID-19 vaccination.
Highlights
Recent reports by Márquez et al described two patients, one of which was in the placebo group, developing Guillain-Barré syndrome (GBS) within 2 weeks of injection with the Johnson & Johnson COVID-19 vaccine, which incorporates a recombinant, adenovirus serotype 26 vector encoding a full-length and stabilized SARS-CoV-2 spike protein
We present a case of bifacial diplegia 4 weeks post the Janssen COVID-19 vaccination in a previously healthy 41-year-old male
According to diagnostic criteria proposed by Wakerly et al [12], our case demonstrates bifacial symmetrical weakness and limb areflexia; absence of limb, neck, or ocular weakness; distal paresthesia at the onset of weakness; and cerebrospinal fluid (CSF) albuminocytological dissociation. We propose this unique case as a rare subtype of GBS in post-COVID-19 vaccination context due to its chronology, clinical manifestations, and CSF findings
Summary
The patient finished 5 days of IVIG treatment with mild side-effects, including nausea and headache. Patient followed in outpatient clinic had MRI imaging of brain showed incidental finding of colloid cyst, no facial nerve enhancement, no mass lesion, no abnormal le4p06tomeningeal (Figure 2). Recent reports by Márquez et al described two patients, one of which was in the placebo group, developing GBS within 2 weeks of injection with the Johnson & Johnson COVID-19 vaccine, which incorporates a recombinant, adenovirus serotype 26 vector encoding a full-length and stabilized SARS-CoV-2 spike protein.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
